TABLE 2.

APRIORI-SD results on the detection of prognostic factors describing patients with better glycemic control.

Subgroup Ranking a	Subgroup description	WRAcc Discovery	WRAcc Test
S1	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND Self-monitoring testing performed at bed time = No	3.30E-2	2.52E-2
S2	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND Self-monitoring testing performed at bed time = No AND # of sorts of required hospitalization (macro/microvascular, hypo) = 0	3.30E-2	2.47E-2
S3	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND # of sorts of required hospitalization (macro/microvascular, hypo) = 0	3.29E-2	2.82E-2
S4	Last postprandial glucose measurement (mg/dL) $\le$ 144	3.29E-2	2.91E-2
S5	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND Self-monitoring testing performed at bed time = No AND Receives GLP-1 analogues = No	3.28E-2	2.38E-2
S6	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND Receives amylin agonist = No AND Receives GLP-1 analogues = No	3.27E-2	2.77E-2
S7	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND Receives GLP-1 analogues = No AND # of sorts of required hospitalization (macro/microvascular, hypo) = 0	3.27E-2	2.68E-2
S8	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND Receives GLP-1 analogues = Yes	3.27E-2	2.77E-2
S9	Last postprandial glucose measurement (mg/dL) $\le$ 144 AND Self-monitoring testing performed at bed time = No AND Receives amylin agonist = No	3.27E-2	2.46E-2
S10	Follow healthy diet and exercise plan = Yes AND Receives more than 2 OGLD = No AND Patient living in = Urban area	3.08E-2	3.43E-2

^aSubgroup ranking is based on WRAcc measure in discovery dataset.